Since the late 1980s, New York physician Nicholas J. Gonzalez has treated patients suffering from late stage pancreatic cancer with an individualized regimen of proteolytic pancreatic enzymes, an ovo-lacto vegetarian diet with nutritional supplementation, and various detoxification procedures such as daily coffee enemas. Gonzalez claims that, compared to chemotherapy, his regimen increases the survival time and quality of life of these patients, but many medical practitioners and critics doubt this claim and refute the theoretical basis of his therapy. This research project critically examines four of the most relevant studies of the Gonzalez therapy, including his 1999 pilot study, a 2007 collection of case reports, a critical analysis of his therapy, and a 2010 National Cancer Institute-backed clinical trial that compared gemcitabane-based chemotherapies against the Gonzalez therapy. A critical examination of the literature finds that, although the pilot study suggested that the Gonzalez therapy was effective at prolonging the survival times of advanced pancreatic cancer patients, the most recent evidence from a well-designed, controlled clinical trial shows that, compared to standard chemotherapy, the Gonzalez therapy fails to prolong patient lives with better quality of life.